4881 Stock Overview
Engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
FunPep Company Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥184.00 |
52 Week High | JP¥325.00 |
52 Week Low | JP¥118.00 |
Beta | 0.74 |
11 Month Change | 17.95% |
3 Month Change | 19.48% |
1 Year Change | -3.16% |
33 Year Change | -56.91% |
5 Year Change | n/a |
Change since IPO | -76.41% |
Recent News & Updates
Shareholder Returns
4881 | JP Biotechs | JP Market | |
---|---|---|---|
7D | 9.5% | 2.5% | 2.1% |
1Y | -3.2% | -7.7% | 20.8% |
Return vs Industry: 4881 exceeded the JP Biotechs industry which returned -7.7% over the past year.
Return vs Market: 4881 underperformed the JP Market which returned 20.8% over the past year.
Price Volatility
4881 volatility | |
---|---|
4881 Average Weekly Movement | 6.5% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 3.8% |
10% most volatile stocks in JP Market | 7.3% |
10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4881 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4881's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 15 | Toshimi Miyoshi | www.funpep.co.jp |
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis.
FunPep Company Limited Fundamentals Summary
4881 fundamental statistics | |
---|---|
Market cap | JP¥4.79b |
Earnings (TTM) | -JP¥760.00m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.3x
P/E RatioIs 4881 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4881 income statement (TTM) | |
---|---|
Revenue | JP¥0 |
Cost of Revenue | JP¥0 |
Gross Profit | JP¥0 |
Other Expenses | JP¥760.00m |
Earnings | -JP¥760.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | -29.22 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 4881 perform over the long term?
See historical performance and comparison